![]()
|
|
||||||||
J. Biol. Chem., Vol. 275, Issue 29, 22395-22400, July 21, 2000
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
From the
Received for publication, March 21, 2000, and in revised form, April 27, 2000
We have isolated KCNQ5, a novel human member of
the KCNQ potassium channel gene family that is differentially expressed
in subregions of the brain and in skeletal muscle. When expressed in
Xenopus oocytes, KCNQ5 generated
voltage-dependent, slowly activating
K+-selective currents that displayed a marked inward
rectification at positive membrane voltages. KCNQ5 currents were
insensitive to the K+ channel blocker tetraethylammonium
but were strongly inhibited by the selective M-current blocker
linopirdine. Upon coexpression with the structurally related KCNQ3
channel subunit, current amplitudes increased 4-5-fold. Compared with
homomeric KCNQ5 currents, KCNQ3/KCNQ5 currents also displayed slower
activation kinetics and less inward rectification, indicating that
KCNQ5 combined with KCNQ3 to form functional heteromeric channel
proteins. This functional interaction between KCNQ5 and KCNQ3, a
component of the M-channel, suggests that KCNQ5 may contribute to a
diversity of heteromeric channels underlying native neuronal
M-currents.
Voltage-dependent potassium channels are key
regulators of the resting membrane potential and modulate the
excitability of electrically active cells, such as neurons and
myocytes. Several classes of voltage-dependent
K+ channels have been cloned, and probably all form
oligomeric proteins through the assembly of four The KCNQ family of voltage-dependent K+
channels was originally established by positional cloning of the
KCNQ1 gene (1), which encodes a K+ channel
protein (KvLQT1) with six transmembrane domains and a characteristic
pore region. So far, the KCNQ family consists of four members, all of
which are associated with hereditary human diseases. KCNQ1 functionally
interacts with KCNE1 (IsK) (2), a small KCNQ2 and KCNQ3 express and colocalize in various subregions of the
brain (16-20). KCNQ2 and KCNQ3 were cloned by linkage to benign
familial neonatal convulsions, a form of epilepsy in human infants.
Missense mutations in either KCNQ2 or KCNQ3 are associated with benign
familial neonatal convulsions (16, 21, 22). Since epilepsy is due to an
electrical hyperexcitability in the brain, members of the
KCNQ gene family may play an important stabilizing role in
the nervous system. Whereas KCNQ2 expresses K+ currents
very similar to KCNQ1 (16, 17, 19, 20), KCNQ3 alone produces much
smaller amplitude currents (17, 19). Coexpression in Xenopus
oocytes of both KCNQ2 and KCNQ3 results in currents that are about
10-fold larger than those expressed by KCNQ2 alone (17-19) and that
also display altered biophysical and pharmacological properties,
suggesting that novel channels are formed by the heteromeric association of KCNQ2 and KCNQ3 subunits. The biophysical and
pharmacological profiles of KCNQ2/KCNQ3 currents expressed in
Xenopus oocytes are very similar to that of the native
neuronal M-type K+ current (19, 23), which is thought to be
a prominent regulator of neuronal excitability. Similar to the native
M-current, KCNQ2/KCNQ3 channel activity is strongly reduced by
muscarinic acetylcholine agonists (19, 24, 25), and therefore it is now
accepted that KCNQ2/KCNQ3 heteromeric channels form the native
M-channel.
KCNQ4, another member of this gene family, is expressed in sensory
outer hair cells of the cochlea and is mutated in one form of
nonsyndromic autosomal dominant deafness (DFNA2) (26, 27). Interestingly, coexpression of KCNQ3 with KCNQ4 in Xenopus
oocytes also increases current amplitudes (26), although to a far less extent than observed with KCNQ2/KCNQ3 coexpression. This raises the
possibility that different KCNQ channel subunits can combine to produce
variants of M-currents in different parts of the nervous system.
In the present work, we have cloned and characterized a novel member of
the KCNQ extended gene family. When functionally expressed in
Xenopus oocytes KCNQ5 produced K+ channels
activated by depolarization, with kinetic properties similar to other
KCNQ channels. KCNQ5 was expressed in skeletal muscle and in the brain,
where its expression pattern overlaps with those of KCNQ2 and KCNQ3,
which underlie the native M-current. Similar to KCNQ2, KCNQ5 formed
functional heteromers with KCNQ3 that produced larger current
amplitudes and were sensitive to block by linopirdine, an
M-channel-specific inhibitor, suggesting that neuronal M-channels may
possibly include heteromeric variants composed of KCNQ3, combined with
KCNQ2, KCNQ5, or other members of the KCNQ gene family.
Molecular Cloning and Expression of KCNQ5--
The
KCNQ5 gene was initially identified as a genomic survey
sequence (bacterial artificial chromosome clone) in a homology search
of GenBankTM (accession number AQ344243). Using this
sequence, a human brain cDNA library (Edge BioSystems) was
screened. A composite full-length cDNA construct was assembled from
two overlapping cDNA clones and subcloned into the
Xenopus expression vector pSGEM (28). The cDNA was fully
sequenced on both strands using an automated DNA sequencer (ABI 310).
For Xenopus oocyte expression, capped cRNA was synthesized
using the T7 mMessage mMachine kit (Ambion). For Northern blot
analysis, a DIG1-labeled
riboprobe of 1.6 kb in length (containing mainly C-terminal sequences)
was generated with the DIG RNA Labeling kit (Roche Molecular
Biochemicals) according to the manufacturer's instructions and
hybridized to a series of human RNA blots
(CLONTECH). Membranes were exposed for 4 min on a
Lumi-Imager (Roche Molecular Biochemicals).
Chromosomal Localization of KCNQ5 Electrophysiology--
Xenopus laevis oocytes were
obtained from tricaine-anesthetized animals. Ovaries were
collagenase-treated (1 mg/ ml; Worthington, type II) in OR2 solution
(82.5 mM NaCl, 2 mM KCl, 1 mM
MgCl2, 5 mM HEPES, pH 7.4) for 120 min and
subsequently stored in recording solution ND96 (96 mM NaCl,
2 mM KCl, 1.8 mM CaCl2, 1 mM MgCl2, 5 mM HEPES, pH 7.4) with
additional sodium pyruvate (275 mg/liter), theophylline (90 mg/liter),
and gentamycin (50 mg/liter) at 18 °C. Oocytes were individually
injected with 10 ng of cRNA encoding hKCNQ5, rKCNQ3, hKCNQ2, and hKCNQ1
or coinjected with 10 ng of hKCNQ5 plus 5 ng of hIsk (KCNE1), hMiRP1
(KCNE2), hMiRP2 (KCNE3), or mMiRP3 (KCNE4), respectively. rKCNQ3 was
cloned from a Cloning and Tissue Distribution of KCNQ5--
A search of the
GenBankTM data base revealed a human bacterial artificial
chromosome end sequence (AQ344243) with significant homology to the
KCNQ potassium channel family. The sequence information was used to
isolate overlapping cDNA clones from a human brain cDNA library
(Edge BioSystems), and two cDNA clones were assembled to generate a
full-length cDNA clone. The initiator methionine of the cDNA
was assigned to the first ATG in frame and is preceded by a stop codon
in the same frame. The full-length KCNQ5 cDNA encodes a protein of
932 amino acids (Fig. 1) with a predicted molecular mass of ~102 kDa. Hydropathy analysis supported a
topological model with six transmembrane domains. KCNQ5 shows
significant homology to other KCNQ predicted proteins, with KCNQ4 being
the closest relative (65% identity). KCNQ5 is about 50% identical to
KCNQ3 and KCNQ2 but only 40% to KCNQ1. Homology is observed, in
particular, throughout the membrane-spanning regions and the conserved
pore region between transmembrane segments S5 and S6. Predicted KCNQ
proteins are characterized by long C-terminal tails. Among the known
KCNQ proteins, KCNQ5 has the longest C terminus, followed by KCNQ2 and
KCNQ3. A distinct region of high sequence conservation was found in the
KCNQ5 C-terminal tail, shared with the other KCNQ proteins. This region
is frequently the site of clinical mutations of other KCNQ proteins
associated with hereditary diseases (8, 12, 17). A recent report
suggests that deletion of the conserved C-terminal domain of KCNQ1
found in a Jervell and Lange-Nielsen syndrome pedigree disrupts
homotypic subunit assembly (29). In addition, in a benign familial
neonatal convulsions pedigree, a 56-amino acid extension in the length
of the KCNQ2 C-terminal tail caused by a frameshift mutation at the
3'-end of the open reading frame, lowers current amplitudes drastically when expressed in Xenopus oocytes. In contrast, truncation
of the last seven natural amino acids increases channel activity 2-fold
(30). Together, these results stress the functional importance of the
C-terminal region in the KCNQ proteins.
The KCNQ5 protein contains numerous potential sites for phosphorylation
by protein kinase C but lacks an N-terminal consensus site for
cAMP-dependent phosphorylation that is present in KCNQ1 and
KCNQ2. KCNQ1 and IKs currents are stimulated by
protein kinase A (6, 31), whereas conflicting data have been reported
concerning the effect of protein kinase A on KCNQ2 currents (17,
20).
Northern blot analyses (Fig. 2) detected
a 7.5-kb KCNQ5 transcript in human adult skeletal muscle and brain. In
the brain, KCNQ5 transcripts are widely distributed with strongest
expression in cerebral cortex, occipital pole, frontal lobe, and
temporal lobe. Lower levels of expression were detected in hippocampus and putamen. The expression pattern of KCNQ5 in the brain is very similar to that previously described for KCNQ2 and KCNQ3 (16-18), with
transcript sizes of 8.5 and 10.5 kb, respectively. Notably, in contrast
to KCNQ2, KCNQ5 is greatly reduced or absent in cerebellum. KCNQ5
probably is the only KCNQ channel subunit strongly expressed in
skeletal muscle. However, the presence of N-terminal splice variants of
KCNQ1 (6) and faint expression levels of KCNQ4 (26) has been reported
in skeletal muscle as well. In contrast to the presence of transcripts,
KCNQ-like currents have not been observed in skeletal muscle. Whether
KCNQ5 and related KCNQ channels contribute to electrical signaling in
skeletal muscle, therefore, remains unknown.
Expression of KCNQ5 in Xenopus Oocytes--
The possible function
of KCNQ5 as a potassium channel was addressed by electrophysiological
analysis of Xenopus oocytes injected with KCNQ5 cRNA
transcribed in vitro. Two to four days after injection, novel currents were detected that were not observed in water-injected control oocytes. Currents activated very slowly (Fig.
3A) and were not fully
activated even after 3-s test pulses. At lower step potentials, KCNQ5
currents showed a delay in activation, similar to KCNQ1 currents (32).
In most cells (in 23 out of 28 oocytes) activation traces above +20 mV
displayed a "crossover" phenomenon, which was observed
independently of current amplitudes. Activation of KCNQ5 currents was
generally slower than that of other KCNQ currents and could be well
described by a second order exponential function, with time constants
of 119 ± 7 and 929 ± 51 ms at +40 mV (Table
I). Current-voltage relationships of
KCNQ5 currents are shown in Fig. 3B. Currents were activated
at depolarizing potentials positive to
To examine the K+ selectivity of KCNQ5, tail current
reversal potentials were determined in bath solutions containing 5.4, 9.6, 20, 54, and 96 mM K+. A 10-fold reduction
in external K+ shifted the reversal potential by about 58 mV (Fig. 3C), indicating nearly perfect selectivity for
K+.
Next we investigated the pharmacological properties of KCNQ5 (protocols
as described in the legend to Fig.
4D; data not shown). KCNQ5
currents were only weakly sensitive to the nonselective K+
channel blocker TEA. The IC50 value of TEA was Functional Interaction of KCNQ5 and KCNQ3--
All members of the
KCNQ family form functional heteromeric complexes with homologous or
structurally different K+ channel subunits. To investigate
the possibility that KCNQ5 might also form heteromeric channels, we
coexpressed KCNQ5 with other KCNQ proteins and with cDNAs encoding
different KCNE proteins.
After coexpression with either KCNQ1 or KCNQ2, or with any of the four
known KCNE proteins (KCNE1 through KCNE4), we failed to detect evidence
for functional interaction of any of these proteins with KCNQ5.
However, coexpression of KCNQ5 with KCNQ3 (Fig. 4A) produced
currents strikingly different from those produced by either KNCQ5 or
KCNQ3 alone. Whereas KCNQ3 expressed very small amplitude currents
almost indistinguishable from background level, in agreement with
previous findings (17, 19), coinjection with KCNQ5 yielded 4-5 times
larger currents than KCNQ5 alone (Fig. 4, A and
C). There was no significant shift in the voltage dependence
of the currents (Fig. 4B), but the I-V
relationship indicated that KCNQ5/KCNQ3 currents were less inwardly
rectifying at positive membrane potentials.
The increase in current amplitude was accompanied by slight changes in
activation kinetics, as shown in Table I. Coexpression of KCNQ5 with
KCNQ3 significantly slowed the fast component of activation
(KCNQ5/KCNQ3
The large increase in current amplitudes, the differences in gating
kinetics observed after coexpression, and the colocalization of KCNQ5
with KCNQ3 in distinct subregions of the brain all indicate that KCNQ5
can associate with KCNQ3 to form functional heteromeric channels.
The functional interaction between KCNQ5 and KCNQ3, a molecular
component of the neuronal M-current, and the sensitivity of KCNQ5 to
the M-channel blocker linopirdine suggest that KCNQ5 may also
contribute to the molecular diversity of this physiologically important current.
For better comparison of the kinetic properties of KCNQ3/KCNQ5
heteromers with those of the native M-current and with KCNQ2/KCNQ3 currents heterologously expressed in Xenopus oocytes, we
used a classical M-current protocol. Starting from a holding potential of
M-currents are found in peripheral and central neurons but have not
been described in cerebellum (19). Interestingly, KCNQ5 and KCNQ3
transcripts are only weakly or not expressed in cerebellum (17-19), in
contrast to KCNQ2, which is strongly expressed (16, 18, 19).
KCNQ4 also can functionally interact with KCNQ3 (26) to yield M-like
currents, raising the possibility that heterogeneous populations of
M-channels exist within the peripheral and central nervous system,
varying in kinetic and pharmacological properties. Heterogeneity in the
molecular composition of M-like channels may possibly be further
increased by contributions of K+ channels from other
potassium channel gene families (38, 39).
The possibility that the KCNQ5 protein may contribute to M-currents
within the brain renders the KCNQ5 gene a candidate genetic locus for epileptic disease. By fluorescence in situ
hybridization analysis, we mapped the KCNQ5 gene to
chromosome 6q14. There are two known loci on chromosome 6 linked to
epileptic diseases, a cloned gene at 6q24 (EPM2A), which is
defective in progressive myoclonic epilepsy type 2 (40, 41), and an
unknown gene mapped to 6p12-p11, which is responsible for juvenile
myoclonic epilepsy (JME) (42). Although our mapping results probably
exclude involvement of KCNQ5 in JME, the identification of KCNQ5 makes
it now possible to investigate possible associations with other forms
of epilepsy or inherited neurological diseases.
We thank Uwe Gerlach for providing chromanol
293B and Alex Yuan for helpful comments on the manuscript.
*
The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
The nucleotide sequence(s) reported in this paper has been submitted to the GenBankTM/EMBL Data Bank with accession number(s) AF249278.
§
These authors contributed equally to this work.
**
To whom correspondence should be addressed. Tel.: 49-69-305-3416;
Fax: 49-69-305-16393; E-mail: Klaus.Steinmeyer@aventis.com.
Published, JBC Papers in Press, April 27, 2000, DOI 10.1074/jbc.M002378200
The abbreviations used are:
DIG, digoxigenin;
IKs, slow component of the cardiac delayed
rectifier current;
kb, kilobase(s);
TEA, tetraethylammonium.
Molecular Cloning and Functional Expression of KCNQ5, a Potassium
Channel Subunit That May Contribute to Neuronal M-current
Diversity*
§,
§,
,
,
, and
**
Aventis Pharma Deutschland GmbH, DG
Cardiovascular Diseases, D-65926 Frankfurt am Main, Germany,
¶ Institute for Physiology, Philipps University, D-35033 Marburg,
Germany, and the
Department of Anatomy and Neurobiology,
Washington University School of Medicine,
St. Louis, Missouri 63110
![]()
ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS AND DISCUSSION
REFERENCES
![]()
INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS AND DISCUSSION
REFERENCES
-protein subunits.
The tetrameric pore complex can further interact with auxiliary
subunits to enhance and/or modify currents mediated by the pore-forming
-subunits.
-subunit protein with a
single transmembrane domain, to generate the slowly activating delayed
rectifier IKs current of cardiomyocytes (3-6).
Deleterious mutations in either subunit result in prolongation of the
cardiac action potential and an increased risk of ventricular
arrhythmia in patients with long QT-syndrome (7-10). Both KCNQ1 and
KCNE1 are also expressed in the inner ear, and a class of recessive
mutations of either gene is associated with hearing loss (11, 12). In
intestine, KCNQ1 probably associates with the IsK-like KCNE3 protein
(13) to generate a distinct K+ current (14). This
KCNQ1/KCNE3 channel complex may represent the native basolateral
cAMP-regulated K+ conductance in colonic crypt cells (15),
important for apical cAMP-stimulated chloride secretion associated with
secretory diarrhea and cystic fibrosis.
![]()
EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS AND DISCUSSION
REFERENCES
Fluorescence in
situ hybridization (Genome Systems) analysis was performed to
determine the chromosomal localization of KCNQ5. Briefly, purified DNA
from the bacterial artificial chromosome clone (AQ344243) was labeled with digoxigenin dUTP by nick translation, and the labeled probe was
hybridized to human metaphase chromosomes derived from
phytohemagglutinin-stimulated peripheral blood lymphocytes.
KCNQ5-specific signals were detected on the long arm of chromosome 6 using fluoresceinated antidigoxigenin antibodies followed by
counterstaining with 4',6-diamidino-2-phenylindole.
ZAP cDNA library (Stratagene) using a DIG-labeled
(Roche Molecular Biochemicals) expressed sequence tag clone
(GenBankTM accession number AA019129) as a probe. hMiRP1
and hMiRP2 were cloned from human genomic DNA, and mMiRP3 was cloned
from murine brain cDNA using primers derived from the published
sequences (13). Standard two-electrode voltage clamp recordings were
performed at room temperature with a Turbo Tec 10CD (NPI) amplifier, an ITC-16 interface combined with Pulse software (Heka) and Origin version
5.0 (Microcal Software) for data acquisition on a Pentium II PC.
Macroscopic currents were recorded 2-4 days after injection. The
pipette solution contained 3 M KCl. All fitting procedures were based on the simplex algorithm. Student's t test was
used to test for statistical significance, which was assumed if
p < 0.05 and indicated by an asterisk.
GenBankTM accession numbers for sequences used are as
follows: hKCNQ1, AJ006345; hKCNQ2, NM004518; rKCNQ3, AF087454;
KCNE1/hIsk, M26685; KCNE2/hMiRP1, AF071002; KCNE3/hMiRP2, AF076531; KCNE4/mMiRP3, AF076533.
![]()
RESULTS AND DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS AND DISCUSSION
REFERENCES

View larger version (85K):
[in a new window]
Fig. 1.
Protein sequence of KCNQ5 and comparison with
other KCNQ proteins. Alignment of human KCNQ5 with human KCNQ1,
KCNQ2, KCNQ3, and KCNQ4 is shown. Identical and conserved amino acids
are boxed in black and gray,
respectively. The six putative transmembrane domains S1 through S6 and
the pore region H5 are indicated by the stippled
lines. The KCNQ5 sequence has been deposited in the
GenBankTM data base under the accession number
AF249278.

View larger version (37K):
[in a new window]
Fig. 2.
Tissue distribution of human potassium
channel KCNQ5. Northern blots of multiple human tissues and
subregions of human brain containing poly(A)+ RNA
(CLONTECH), hybridized with a KCNQ5-specific
DIG-labeled RNA probe.
60 mV and displayed marked
inward rectification at potentials greater than 0 mV (Fig. 3,
A and B). Strong inward rectification only has
been demonstrated for the related KCNQ3 channel (18). KCNQ5
deactivation was fitted to a second order exponential function. Two
components of deactivation, with time constants of 51 ± 2 and
281 ± 24 ms, were observed at a repolarizing voltage of
100 mV,
following a 3-s depolarizing step to +40 mV (Table I). KCNQ1 tail
currents display a characteristic "hook" indicative of recovery
from inactivation (32, 33). We did not observe such a feature for KCNQ5
currents at voltages between
100 and +40 mV. Additionally,
double-pulse protocols commonly used to reveal inactivation (33) also
failed to reveal inactivation (not shown).

View larger version (10K):
[in a new window]
Fig. 3.
Functional expression of KCNQ5 in
Xenopus oocytes. A, representative
current traces from a KCNQ5-injected oocyte subjected to a pulse
protocol stepping the membrane potential from holding potential (
100
mV) to test pulses from
100 to +50 mV, and then back to holding
potential. B, I-V relationships from KCNQ5
currents recorded in oocytes (n = 12), using the
protocol in A. Current amplitudes were normalized to maximum
value. C, tail current reversal potentials of KCNQ5 currents
as a function of extracellular K+ concentration
(n = 5). The dashed line is
calculated by the Nernst equation corresponding to a perfectly
selective K+ channel.
Activation and deactivation time constants of homomeric and heteromeric
KCNQ channels
30
mM and similar to results obtained with KCNQ3 (18, 19, 34).
Consistently, both channel proteins contain threonine residues within
the pore region at a position that mainly determines sensitivity to
external blockade by TEA. While in KCNQ2 a tyrosine residue at this
position confers high TEA sensitivity (19, 35), other residues may be
responsible for the intermediate TEA sensitivity of KCNQ1 and KCNQ4 (6,
34). Another nonspecific potassium channel blocker, quinidine, at 300 µM blocked KCNQ5 currents by 50%. Specific inhibitors of
KCNQ1 and IKs were tested at concentrations that
nearly completely block these currents. The chromanol 293B (36) at 100 µM blocked KCNQ5 currents by 45%. In comparison, KCNQ1
is 80% blocked, and IKs is completely blocked
at this concentration (37). The class III antiarrhythmic agent
clofilium blocks KCNQ1 with an IC50 of <10
µM (6). At 30 µM, clofilium reduced KCNQ5
current by 40%, similar to its inhibitory effect on KCNQ3 (30%
inhibition at 10 µM). Clofilium produces little
inhibition of KCNQ2 at 10 µM (18). Thus, the general
pharmacological properties of KCNQ5 are distinct from KCNQ1 and more
similar to those of KCNQ3 than to KCNQ2. Most importantly, linopirdine,
a specific blocker of the neuronal M-channel very effectively inhibited
KCNQ5 with a Kd value of 16 ± 1 µM.

View larger version (25K):
[in a new window]
Fig. 4.
Functional interaction of KCNQ5 with
KCNQ3. A, representative current traces from an oocyte
coinjected with KCNQ5 and KCNQ3 using the same voltage protocol as in
Fig. 3A. B, I-V relationships of
oocytes expressing KCNQ5 plus KCNQ3 (n = 11). Current
amplitudes normalized to maximum value. C, bar graphs
plotting mean current amplitudes at the end of a 3-s test pulse to +40
mV, from a holding potential of
100 mV. Oocytes injected with cRNA
encoding KCNQ5 (n = 14), KCNQ3 (n = 6),
or KCNQ5 plus KCNQ3 (n = 12), the amount of RNA
injected as described in Table I. Current amplitudes normalized to the
amplitude of KCNQ5. Error bars indicate S.E.
D, concentration dependence of inhibition of KCNQ2/KCNQ3 and
KCNQ3/KCNQ5 by linopirdine. Holding potential was
100 mV, 3-s test
pulse, to 0 mV every 10 s. Each concentration was perfused for 5 min. Inhibition values were obtained at the end of the depolarizing
step and normalized to control (averaged from five oocytes).
Error bars indicate S.E.
fast = 167 ± 14 ms; KCNQ5
fast = 119 ± 7 ms) without altering the slow
activation component and the deactivation kinetics (see Table I).
Compared with KCNQ2/KCNQ3, heteromeric KCNQ5/KCNQ3 channels exhibited
slower activation, whereas deactivation kinetics of both heteromers
were very similar (see Table I).
30 mV, we stepped to
50 mV and determined deactivation kinetics as described by Wang et al. (19). The data obtained for
KCNQ3/KCNQ5 (
fast = 199 ± 10 ms;
slow = 985 ± 60 ms; n = 6) and
KCNQ2/KCNQ3 (
fast = 209 ± 11 ms;
slow = 766 ± 37 ms; n = 6),
respectively, correspond well to the time constants reported for the
native M-current (
fast = 103 ms;
slow = 1041 ms) (19). In addition, similar to homomeric KCNQ5 currents, also
heteromeric KCNQ3/KCNQ5 channels were strongly inhibited by
linopirdine. As shown in Fig. 4D, sensitivity to block by
linopirdine of KCNQ3/KCNQ5 was very similar to that obtained for
KCNQ2/KCNQ3 (IC50 values of 15 ± 2 µM
and 10 ± 1 µM, respectively), further corroborating
the M-like nature of the KCNQ3/KCNQ5 current.
![]()
ACKNOWLEDGEMENTS
![]()
FOOTNOTES
![]()
ABBREVIATIONS
![]()
REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS AND DISCUSSION
REFERENCES
1.
Wang, Q.,
Curran, M. E.,
Splawski, I.,
Burn, T. C.,
Millholla, J. M.,
VanRaay, T. J.,
Shen, J.,
Timothy, K. W.,
Vincent, G. M.,
de Jager, T.,
Schwartz, P. J.,
Towbin, J. A.,
Moss, A. J.,
Atkinson, D. L.,
Landes, G. M.,
Connors, T. D.,
and Keating, M. T.
(1996)
Nat. Genet.
12,
17-23
2.
Takumi, T.,
Ohkubo, H.,
and Nakanishi, S.
(1988)
Science
242,
1042-1044
3.
Attali, B.
(1996)
Nature
384,
24-25
4.
Barhanin, J.,
Lesage, F.,
Guillemare, E.,
Fink, M.,
Lazdunski, M.,
and Romey, G.
(1996)
Nature
384,
78-80
5.
Sanguinetti, M. C.,
Curran, M. E.,
Zou, A.,
Shen, J.,
Spector, P. S.,
Atkinson, D. L.,
and Keating, M. T.
(1996)
Nature
384,
80-83
6.
Yang, W.-P.,
Levesque, P. C.,
Little, W. A.,
Conder, M. L.,
Shalaby, F. Y.,
and Blanar, M. A.
(1997)
Proc. Natl. Acad. Sci. U. S. A.
94,
4017-4021
7.
Keating, M. T.,
and Sanguinetti, M. C.
(1996)
Science
272,
681-685
8.
Chouabe, C.,
Neyroud, N.,
Guicheney, P.,
Lazdunski, M.,
Romey, G.,
and Barhanin, J.
(1997)
EMBO J.
16,
5472-5479
9.
Sanguinetti, M. C.
(1999)
Ann. N. Y. Acad. Sci.
868,
406-413
10.
Suessbrich, H.,
and Busch, A. E.
(1999)
Rev. Physiol. Biochem. Pharmacol.
137,
191-226
11.
Schulze-Bahr, E.,
Wang, Q.,
Wedekind, H.,
Haverkamp, W.,
Chen, Q.,
and Sun, Y.
(1997)
Nat. Genet.
17,
267-268
12.
Neyroud, N.,
Tesson, F.,
Denjoy, I.,
Leibovici, M.,
Donger, C.,
Barhanin, J.,
Faure, S.,
Gary, F.,
Coumel, P.,
Petit, C.,
Schwartz, K.,
and Guicheney, P.
(1997)
Nat. Genet.
15,
186-189
13.
Abbott, G. W.,
Sesti, F.,
Splawski, I.,
Buck, M. E.,
Lehmann, M. H.,
Timothy, K. W.,
Keating, M. T.,
and Goldstein, S. A. N.
(1999)
Cell
97,
175-187
14.
Schröder, B. C.,
Waldegger, S.,
Fehr, S.,
Bleich, M.,
Warth, R.,
Greger, R.,
and Jentsch, T. J.
(2000)
Nature
403,
196-199
15.
Lohrmann, E.,
Burhoff, I.,
Nitschke, R. B.,
Lang, H.-J.,
Mania, D.,
Englert, H. C.,
Hropot, M.,
Warth, R.,
Rohm, W.,
Bleich, M.,
and Greger, R.
(1995)
Pflügers Arch.
429,
517-530
16.
Biervert, C.,
Schröder, B. C.,
Kubisch, C.,
Berkovic, S. F.,
Propping, P.,
Jentsch, T. J.,
and Steinlein, O. K.
(1998)
Science
279,
403-406
17.
Schröder, B. C.,
Kubisch, C.,
Stein, V.,
and Jentsch, T. J.
(1998)
Nature
396,
687-690
18.
Yang, W.-P.,
Levesque, P. C.,
Little, W. A.,
Conder, M. L.,
Ramakrishnan, P.,
Neubauer, M. G.,
and Blanar, M. A.
(1998)
J. Biol. Chem.
273,
19419-19423
19.
Wang, H.-S.,
Pan, Z.,
Shi, W.,
Brown, B. S.,
Wymore, R. S.,
Cohen, I. S.,
Dixon, J. E.,
and McKinnon, D.
(1998)
Science
282,
1890-1893
20.
Tinel, N.,
Lauritzen, I.,
Chouabe, C.,
Lazdunski, M.,
and Borsotto, M.
(1998)
FEBS Lett.
438,
171-176
21.
Singh, N. A.,
Charlier, C.,
Stauffer, D.,
DuPont, B. R.,
Leach, R. J.,
Melis, R.,
Ronen, G. M.,
Bjerre, I.,
Quattlebaum, T.,
Murphy, J. V.,
McHarg, M. L.,
Gagnon, D.,
Rosales, T. O.,
Peiffer, A.,
Anderson, V. E.,
and Leppert, M.
(1998)
Nat. Genet.
18,
25-29
22.
Charlier, C.,
Singh, N. A.,
Ryan, S. G.,
Lewis, T. B.,
Reus, B. E.,
Leach, R. J.,
and Leppert, M.
(1998)
Nat. Genet.
18,
53-55
23.
Brown, D. A.,
and Adams, P. R.
(1980)
Nature
283,
673-676
24.
Shapiro, M. S.,
Roche, J. P.,
Kaftan, E. J.,
Cruzblanca, H.,
Mackie, K.,
and Hille, B.
(2000)
J. Neurosci.
20,
1710-1721
25.
Selyanko, A. A.,
Hadley, J. K.,
Wood, I. C.,
Abogadie, F. C.,
Jentsch, T. J.,
and Brown, D. A.
(2000)
J. Physiol.
522,
349-355
26.
Kubisch, C.,
Schröder, B. C.,
Friedrich, T.,
Lütjohann, B.,
El-Amraoui, A.,
Marlin, S.,
Petit, C.,
and Jentsch, T. J.
(1999)
Cell
96,
437-446
27.
Coucke, P. J.,
Van Hauwe, P.,
Kelley, P. M.,
Kunst, H.,
Schatteman, I.,
Van Velzen, D.,
Meyers, J.,
Ensink, R. J.,
Verstreken, M.,
Declau, F.,
Marres, H.,
Kastury, K.,
Bhasin, S.,
McGuirt, W. T.,
Smith, R. J.,
Cremers, C. W.,
Van de Heyning, P.,
Willems, P. J.,
Smith, S. D.,
and Van Camp, G.
(1999)
Hum. Mol. Genet.
8,
1321-1328
28.
Villmann, C.,
Bull, L.,
and Hollmann, M.
(1997)
J. Neurosci.
17,
7634-7643
29.
Schmitt, N.,
Schwarz, M.,
Peretz, A.,
Abitbol, I.,
Attali, B.,
and Pongs, O.
(2000)
EMBO J.
19,
332-340
30.
Lerche, H.,
Biervert, C.,
Alekov, A. K.,
Schleithoff, L.,
Lindner, M.,
Klinger, W.,
Bretschneider, F.,
Mitrovic, N.,
Jurkat-Rott, K.,
Bode, H.,
Lehmann-Horn, F.,
and Steinlein, O. K.
(1999)
Ann. Neurol.
46,
305-312
31.
Sanguinetti, M. C.,
Jurkiewicz, N. K.,
Scott, A.,
and Siegl, P. K. S.
(1991)
Circ. Res.
68,
77-84
32.
Pusch, M.,
Magrassi, R.,
Wollnik, B.,
and Conti, F.
(1998)
Biophys. J.
75,
785-792
33.
Tristani-Firouzi, M,
and Sanguinetti, M. C.
(1998)
J. Physiol.
510,
37-45
34.
Hadley, J. K.,
Noda, M.,
Selyanko, A. A.,
Wood, I. C.,
Abogadie, F. C.,
and Brown, D. A.
(2000)
Br. J. Pharmacol.
129,
413-415
35.
MacKinnon, R.,
and Yellen, G.
(1990)
Science
250,
276-279
36.
Suessbrich, H.,
Bleich, M.,
Ecke, D.,
Rizzo, M.,
Waldegger, S.,
Lang, F.,
Szabo, I.,
Lang, H.-J.,
Kunzelmann, K.,
Greger, R.,
and Busch, A. E.
(1996)
FEBS Lett.
396,
271-275
37.
Busch, A. E.,
Busch, G. L.,
Ford, E.,
Suessbrich, H.,
Lang, H.-J.,
Greger, R.,
Kunzelmann, K.,
Attali, B.,
and Stühmer, W.
(1997)
Br. J. Pharmacol.
122,
187-189
38.
Meves, H.,
Schwarz, J. R.,
and Wulfsen, I.
(1999)
Br. J. Pharmacol.
127,
1213-1223
39.
Selyanko, A. A.,
Hadley, J. K.,
Wood, I. C.,
Abogadie, F. C.,
Delmas, P.,
Buckley, N. J.,
London, B.,
and Brown, D. A.
(1999)
J. Neurosci.
19,
7742-7756
40.
Minassian, B. A.,
Lee, J. R.,
Herbrick, J. A.,
Huizenga, J.,
Soder, S.,
Mungall, A. J.,
Dunham, I.,
Gardner, R.,
Fong, C. Y.,
Carpenter, S.,
Jardim, L.,
Satishchandra, P.,
Andermann, E.,
Snead, O. C.,
Lopes-Cendes, I.,
Tsui, L. C.,
Delgado-Escueta, A. V.,
Rouleau, G. A.,
and Scherer, S. W.
(1998)
Nat. Genet.
20,
171-174
41.
Serratosa, J. M.,
Gomez-Garre, P.,
Gallardo, M. E.,
Anta, B.,
deBernabe, D. B.,
Lindhout, D.,
Augustijn, P. B.,
Tassinari, C. A.,
Malafosse, R. M.,
Topcu, M.,
Grid, D.,
Dravet, C.,
Berkovic, S. F.,
and deCordoba, S. R.
(1999)
Hum. Mol. Genet.
8,
345-352
42.
Liu, A. W.,
Delgado-Escueta, A. V.,
Gee, M. N.,
Serratosa, J. M.,
Zhang, Q. W.,
Alonso, M. E.,
Medina, M. T.,
Cordova, S.,
Zhao, H. Z.,
Spellman, J. M.,
Rubio Donnadieu, F.,
Ramos Peek, J.,
Treiman, L. J.,
and Sparkes, R. S.
(1996)
Am. J. Med. Genet.
63,
438-446
Copyright © 2000 by The American Society for Biochemistry and Molecular Biology, Inc.
![]()
CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
Technorati What's this?
This article has been cited by other articles:
![]() |
O. Zaika, C. C. Hernandez, M. Bal, G. P. Tolstykh, and M. S. Shapiro Determinants within the Turret and Pore-Loop Domains of KCNQ3 K+ Channels Governing Functional Activity Biophys. J., December 1, 2008; 95(11): 5121 - 5137. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Bal, J. Zhang, O. Zaika, C. C. Hernandez, and M. S. Shapiro Homomeric and Heteromeric Assembly of KCNQ (Kv7) K+ Channels Assayed by Total Internal Reflection Fluorescence/Fluorescence Resonance Energy Transfer and Patch Clamp Analysis J. Biol. Chem., November 7, 2008; 283(45): 30668 - 30676. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. R. Mackie and K. L. Byron Cardiovascular KCNQ (Kv7) Potassium Channels: Physiological Regulators and New Targets for Therapeutic Intervention Mol. Pharmacol., November 1, 2008; 74(5): 1171 - 1179. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Nakajo and Y. Kubo Second coiled-coil domain of KCNQ channel controls current expression and subfamily specific heteromultimerization by salt bridge networks J. Physiol., June 15, 2008; 586(12): 2827 - 2840. [Abstract] [Full Text] [PDF] |
||||
![]() |
Z. Jia, J. Bei, L. Rodat-Despoix, B. Liu, Q. Jia, P. Delmas, and H. Zhang NGF Inhibits M/KCNQ Currents and Selectively Alters Neuronal Excitability in Subsets of Sympathetic Neurons Depending on their M/KCNQ Current Background J. Gen. Physiol., June 1, 2008; 131(6): 575 - 587. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Xu, L. Nie, Y. Zhang, J. Mo, W. Feng, D. Wei, E. Petrov, L. E. Calisto, B. Kachar, K. W. Beisel, et al. Roles of Alternative Splicing in the Functional Properties of Inner Ear-specific KCNQ4 Channels J. Biol. Chem., August 17, 2007; 282(33): 23899 - 23909. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Lerche, I. Bruhova, H. Lerche, K. Steinmeyer, A. D. Wei, N. Strutz-Seebohm, F. Lang, A. E. Busch, B. S. Zhorov, and G. Seebohm Chromanol 293B Binding in KCNQ1 (Kv7.1) Channels Involves Electrostatic Interactions with a Potassium Ion in the Selectivity Filter Mol. Pharmacol., June 1, 2007; 71(6): 1503 - 1511. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. S. Jensen, M. Grunnet, and S.-P. Olesen Inactivation as a New Regulatory Mechanism for Neuronal Kv7 Channels Biophys. J., April 15, 2007; 92(8): 2747 - 2756. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Koyama, M. S. Brodie, and S. B. Appel Ethanol Inhibition of M-Current and Ethanol-Induced Direct Excitation of Ventral Tegmental Area Dopamine Neurons J Neurophysiol, March 1, 2007; 97(3): 1977 - 1985. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Balbir, H. Lee, M. Okumura, S. Biswal, R. S. Fitzgerald, and M. Shirahata A search for genes that may confer divergent morphology and function in the carotid body between two strains of mice Am J Physiol Lung Cell Mol Physiol, March 1, 2007; 292(3): L704 - L715. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. I. Brueggemann, C. J. Moran, J. A. Barakat, J. Z. Yeh, L. L. Cribbs, and K. L. Byron Vasopressin stimulates action potential firing by protein kinase C-dependent inhibition of KCNQ5 in A7r5 rat aortic smooth muscle cells Am J Physiol Heart Circ Physiol, March 1, 2007; 292(3): H1352 - H1363. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Peretz, A. Sheinin, C. Yue, N. Degani-Katzav, G. Gibor, R. Nachman, A. Gopin, E. Tam, D. Shabat, Y. Yaari, et al. Pre- and Postsynaptic Activation of M-Channels By a Novel Opener Dampens Neuronal Firing and Transmitter Release J Neurophysiol, January 1, 2007; 97(1): 283 - 295. [Abstract] [Full Text] [PDF] |
||||
![]() |
O. Zaika, L. S. Lara, N. Gamper, D. W. Hilgemann, D. B. Jaffe, and M. S. Shapiro Angiotensin II regulates neuronal excitability via phosphatidylinositol 4,5-bisphosphate-dependent modulation of Kv7 (M-type) K+ channels J. Physiol., August 15, 2006; 575(1): 49 - 67. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. L. Wladyka and D. L. Kunze KCNQ/M-currents contribute to the resting membrane potential in rat visceral sensory neurons J. Physiol., August 15, 2006; 575(1): 175 - 189. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Koyama and S. B. Appel Characterization of M-Current in Ventral Tegmental Area Dopamine Neurons J Neurophysiol, August 1, 2006; 96(2): 535 - 543. [Abstract] [Full Text] [PDF] |
||||
![]() |
Z. Pan, T. Kao, Z. Horvath, J. Lemos, J.-Y. Sul, S. D. Cranstoun, V. Bennett, S. S. Scherer, and E. C. Cooper A common ankyrin-G-based mechanism retains KCNQ and NaV channels at electrically active domains of the axon. J. Neurosci., March 8, 2006; 26(10): 2599 - 2613. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. V. Dzhura, W. He, and K. P. M. Currie Linopirdine Modulates Calcium Signaling and Stimulus-Secretion Coupling in Adrenal Chromaffin Cells by Targeting M-Type K+ Channels and Nicotinic Acetylcholine Receptors J. Pharmacol. Exp. Ther., March 1, 2006; 316(3): 1165 - 1174. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. V. Soldovieri, P. Castaldo, L. Iodice, F. Miceli, V. Barrese, G. Bellini, E. M. del Giudice, A. Pascotto, S. Bonatti, L. Annunziato, et al. Decreased Subunit Stability as a Novel Mechanism for Potassium Current Impairment by a KCNQ2 C Terminus Mutation Causing Benign Familial Neonatal Convulsions J. Biol. Chem., January 6, 2006; 281(1): 418 - 428. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Wen, T. M. Weiger, T. S. Ferguson, M. Shahidullah, S. S. Scott, and I. B. Levitan A Drosophila KCNQ Channel Essential for Early Embryonic Development J. Neurosci., November 2, 2005; 25(44): 10147 - 10156. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Li, N. Gamper, D. W. Hilgemann, and M. S. Shapiro Regulation of Kv7 (KCNQ) K+ Channel Open Probability by Phosphatidylinositol 4,5-Bisphosphate J. Neurosci., October 26, 2005; 25(43): 9825 - 9835. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Gu, K. Vervaeke, H. Hu, and J. F Storm Kv7/KCNQ/M and HCN/h, but not KCa2/SK channels, contribute to the somatic medium after-hyperpolarization and excitability control in CA1 hippocampal pyramidal cells J. Physiol., August 1, 2005; 566(3): 689 - 715. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. D. Wei, A. Butler, and L. Salkoff KCNQ-like Potassium Channels in Caenorhabditis elegans: CONSERVED PROPERTIES AND MODULATION J. Biol. Chem., June 3, 2005; 280(22): 21337 - 21345. [Abstract] [Full Text] [PDF] |
||||